An Efficacy and Safety Study of JNJ-26113100 in the Treatment of Adult Atopic Dermatitis
A Double-Blind, Randomized, Placebo-Controlled, Sequential Cohort Exploratory Study of the Safety and Efficacy of JNJ-26113100 in the Treatment of Adult Atopic Dermatitis That is Moderate in Severity
研究概览
地位
条件
详细说明
This study is a double-blind (neither the researchers nor the participants know what treatment the participant is receiving), randomized (study drug assigned by chance), placebo-controlled (an inactive substance; a pretend treatment [with no drug in it] that is compared in a clinical trial with a drug to test if the drug has a real effect), sequential cohort exploratory study to evaluate the safety and effectiveness of JNJ-26113100 in the treatment of adult AD that is moderate in severity, including its effect on inflammatory biomarkers (biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease). Participants will be sequentially assigned to 50 milligram (mg) once daily, 100 mg once daily, 100 mg twice daily or 250 mg twice daily cohort and randomly assigned to receive JNJ-26113100 or matching placebo.
The total duration of the study will be approximately 8 weeks. Participants will be asked to follow-up at the end of Week 1, 2, 3, 4, 5 and 6. A study termination visit (Day 57) will be conducted at the end of Week 8. Skin biopsies from atopic dermatitis lesions will be collected during the study to assess changes in the inflammatory disease state. Participants developing flares of their disease may be treated with triamcinolone acetonide 0.1 percent ointment twice daily for up to 7 days. Efficacy will be assessed using Investigator's Global Assessment (IGA), Eczema Area and Severity Index (EASI) and Visual Analog Scale (VAS). Blood and urine samples will be collected for standard safety laboratory tests, to measure the level of drug and effect of the drug on inflammatory biomarkers. Participant's safety will be monitored throughout the study.
研究类型
注册 (实际的)
阶段
- 阶段2
联系人和位置
学习地点
-
-
Alabama
-
Huntsville、Alabama、美国
-
-
California
-
Los Angeles、California、美国
-
Sacramento、California、美国
-
San Diego、California、美国
-
Stanford、California、美国
-
Vista、California、美国
-
-
Florida
-
Jacksonville、Florida、美国
-
-
Illinois
-
Chicago、Illinois、美国
-
Skokie、Illinois、美国
-
-
New Mexico
-
Albuquerque、New Mexico、美国
-
-
New York
-
Rochester、New York、美国
-
Stony Brook、New York、美国
-
-
Ohio
-
Sylvania、Ohio、美国
-
-
Oregon
-
Portland、Oregon、美国
-
-
Pennsylvania
-
Philadelphia、Pennsylvania、美国
-
-
Texas
-
College Station、Texas、美国
-
San Antonio、Texas、美国
-
-
Washington
-
Seattle、Washington、美国
-
-
Wisconsin
-
Madison、Wisconsin、美国
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:-Adult participants with Atopic Dermatitis (skin rash, inflammation) involving greater than or equal to 10 percent body surface area
- Female participants must have a negative serum pregnancy test at screening
- With the exception of well-controlled asthma, allergic rhinitis and food allergies, participants must be in good general health prior to study participation with no clinically significant abnormalities as assessed by the investigator and determined by medical history, physical examination, blood chemistry, complete blood count, coagulation tests, urinalysis and electrocardiogram (ECG)
- Male subjects must consent to utilize a medically acceptable method of contraception throughout the study including the washout period and for three months after the study is completed
- Female participants of child bearing potential must consent to utilize a medically acceptable method of contraception throughout the study including the washout period and for three months after the study is completed Exclusion Criteria:-Evidence of clinically significant hepatic, reproductive, gastrointestinal, renal, hematologic, pulmonary, neurologic, respiratory (with the exception of well-controlled asthma), endocrine or cardiovascular abnormalities or psychiatric disorders
- Participants with screening alanine aminotransferase, alkaline phosphatase or direct bilirubin levels above the upper limit of normal
- Evidence of any skin condition that in the opinion of the investigator would interfere with assessment of atopic dermatitis
- Use of any investigational drugs within the previous 30 days prior to dosing or within a period of less than five times the drug's half-life, whichever is longer
- Use of any biologic within a period of 5 times its half-life
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:单组作业
- 屏蔽:四人间
武器和干预
参与者组/臂 |
干预/治疗 |
---|---|
安慰剂比较:安慰剂
|
Matching placebo capsules to JNJ-26113100 (50 milligram [mg]) orally once daily or 100 mg orally once daily or 100 mg orally twice daily or 250 mg orally twice daily for 6 weeks.
|
实验性的:JNJ-26113100 (50 mg) once daily
|
JNJ-26113100 (50 mg) capsules orally once daily for 6 weeks.
|
实验性的:JNJ-26113100 (100 mg) once daily
|
JNJ-26113100 (100 mg) capsules orally once daily for 6 weeks.
|
实验性的:JNJ-26113100 (100 mg) twice daily
|
JNJ-26113100 (100 mg) capsules orally twice daily for 6 weeks.
|
实验性的:JNJ-26113100 (250 mg) twice daily
|
JNJ-26113100 (250 mg) capsules orally twice daily for 6 weeks.
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Investigator's Global Assessment (IGA) Score at Week 6
大体时间:Week 6
|
Participants were reported for IGA.
IGA is an overall assessment of Atopic Dermatitis (AD).
IGA utilizes a 6-point scale (ranging from 0 to 5): 0=clear (noinflammatory signs of AD), 1=almost clear (just perceptible erythema, and just perceptible papulation/infiltration), 2=mild disease (mild erythema, and mild papulation/infiltration), 3=moderate disease (moderate erythema, and moderate papulation/infiltration), 4=severe disease (severe erythema, and severe papulation/infiltration) and 5=very severe disease (severe erythema, and severe papulation/infiltration with oozing/crusting).
|
Week 6
|
Change From Baseline in Eczema Area and Severity Index (EASI) Score at Week 6
大体时间:Baseline and Week 6
|
EASI measures erythema (E), infiltration (I), excoriation (Ex) and lichenification (L) on a scale of 0 (none) to 3 (severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs.
Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no eruption) to 6 (greater than [>] 90%-100% eruption).
The total score is the sum of the four body-region scores, maximum=72, minimum=0, with higher scores reflecting greater disease severity.
The total qualitative score is multiplied by the degree of involvement for each anatomic region and then multiplied by a constant and summed to yield the EASI score.
|
Baseline and Week 6
|
Change From Baseline in Visual Analog Scale (VAS) Score for Pruritus at Week 6
大体时间:Baseline and Week 6
|
VAS consists of 10 centimeter (cm) horizontal line and the words; 0 cm="No itch" on the left side of the line and the words 10 cm="Worst possible itch" on the right side of the line.
Participants will be instructed to rate the severity of their pruritus within the previous 24 hours by drawing a vertical line across the 10 cm line at the point between "No itch" and "Worst possible itch" which best describes their itching during the preceding 24 hours.
|
Baseline and Week 6
|
Percentage of Participants Achieving Treatment Response as "Clear" or "Almost Clear "in IGA
大体时间:Baseline up to Week 6
|
Percentage of participants achieving treatment response (decrease) in IGA were assessed.
IGA is used to assess AD through a 6-point scale (Range=0-5) where, 0=clear (no inflammatory signs of AD), 1=almost clear (just perceptible erythema & perceptible papulation/infiltration), 2=mild (mild erythema & papulation/infiltration), 3=moderate (moderate erythema & papulation/infiltration), 4=severe (severe erythema & papulation/infiltration) & 5=very severe (severe erythema & papulation/infiltration with oozing/crusting).
Success is reduction of IGA to 0 or 1.
Failure is reduction of IGA to >=2.
|
Baseline up to Week 6
|
Percentage of Participants Achieving 50% Reduction in EASI Score at Week 6
大体时间:Baseline up to Week 6
|
EASI measures erythema (E), infiltration (I), excoriation (Ex) and lichenification (L) on a scale of 0 (none) to 3 (severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs.
Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no eruption) to 6 (greater than [>] 90%-100% eruption).
The total score is the sum of the four body-region scores, maximum=72, minimum=0, with higher scores reflecting greater disease severity.
The total qualitative score is multiplied by the degree of involvement for each anatomic region and then multiplied by a constant and summed to yield the EASI score.
Success is defined as an improvement of >=50% from the baseline EASI score.
An improvement of <50% is considered a failure.
|
Baseline up to Week 6
|
Percentage of Participants Achieving Greater Than (>) or Equal to (=) 25% Reduction in EASI Score at Week 6
大体时间:Baseline up to Week 6
|
EASI measures erythema (E), infiltration (I), excoriation (Ex) and lichenification (L) on a scale of 0 (none) to 3 (severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs.
Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no eruption) to 6 (greater than [>] 90%-100% eruption).
The total score is the sum of the four body-region scores, maximum=72, minimum=0, with higher scores reflecting greater disease severity.
The total qualitative score is multiplied by the degree of involvement for each anatomic region and then multiplied by a constant and summed to yield the EASI score.
Success is defined as an improvement of >=25% from the baseline EASI score.
An improvement of <25% is considered a failure.
|
Baseline up to Week 6
|
Percentage of Participants Achieving Greater Than (>) or Equal to (=) 75% Reduction in VAS Score for Pruritus at Week 6
大体时间:Baseline up to Week 6
|
VAS consists of 10 centimeter (cm) horizontal line and the words; 0 cm="No itch" on the left side of the line and the words 10 cm="Worst Possible Itch" on the right side of the line.
Participants will be instructed to rate the severity of their pruritus within the previous 24 hours by drawing a vertical line across the 10 cm line at the point between "No itch" and "Worst possible itch" which best describes their itching during the preceding 24 hours.
Success is defined as an improvement of >=75% from the baseline VAS assessment of pruritus.
An improvement of <75% is a failure.
|
Baseline up to Week 6
|
Percentage of Participants Achieving Greater Than (>) or Equal to (=) 50% Reduction in VAS Score for Pruritus at Week 6
大体时间:Baseline up to Week 6
|
VAS consists of 10 centimeter (cm) horizontal line and the words; 0 cm="No itch" on the left side of the line and the words 10 cm="Worst possible itch" on the right side of the line.
Participants will be instructed to rate the severity of their pruritus within the previous 24 hours by drawing a vertical line across the 10 cm line at the point between "No itch" and "Worst possible itch" which best describes their itching during the preceding 24 hours.
Success is defined as an improvement of >=75% from the baseline VAS assessment of pruritus.
An improvement of <75% is a failure.
|
Baseline up to Week 6
|
Percentage of Participants Achieving Greater Than (>) or Equal to (=) 25% Reduction in VAS Score for Pruritus at Week 6
大体时间:Baseline up to Week 6
|
VAS consists of 10 centimeter (cm) horizontal line and the words; 0 cm="No itch" on the left side of the line and the words 10 cm="Worst possible itch" on the right side of the line.
Participants will be instructed to rate the severity of their pruritus within the previous 24 hours by drawing a vertical line across the 10 cm line at the point between "No itch" and "Worst possible itch" which best describes their itching during the preceding 24 hours.
Success is defined as an improvement of >=75% from the baseline VAS assessment of pruritus.
An improvement of <75% is a failure.
|
Baseline up to Week 6
|
Percentage of Participants Who Had at Least 1 Flare
大体时间:Baseline up to Week 6
|
Percentage of participants who had at Least 1 Flare while on treatment was assessed.
A flare was considered to be present if the following criteria were met: 1) IGA was greater than or equal to 2, if IGA on most recent previous assessment was 0; 2) IGA had increased by at least 1 point, if IGA on most recent previous assessment was 1 or more.
|
Baseline up to Week 6
|
Number of Flare Occurrences Per Participant
大体时间:Baseline up to Week 6
|
A flare was considered to be present if the following criteria were met: 1) IGA was greater than or equal to 2, if IGA on most recent previous assessment was 0 or 2) IGA had increased by at least 1 point, if IGA on most recent previous assessment was 1 or more.
|
Baseline up to Week 6
|
Percentage of Participants Who Had at Least 1 Worsening AD Event
大体时间:Baseline up to Week 6
|
Percentage of Participants who had at least 1 Worsening AD Event That did not Meet Flare Criteria were assessed.
Worsening of AD that did not meet flare criteria was documented.
Flare was considered to be present if either of the following criteria were met: 1) IGA was=2, if IGA on most recent previous assessment was 0; 2) IGA had increased by at least 1 point, if IGA on most recent previous assessment was 1 or more.
|
Baseline up to Week 6
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Plasma Concentration of JNJ-26113100
大体时间:Before dosing on Day 1, Week 3, Week 6; after dosing at 0.25 to 3 hours on Day 1, Week 3, Week 6; after dosing at 4 to 6 hours and 7 to 12 hours on Week 6
|
Blood samples for pharmacokinetic (PK) analysis were collected before dosing and at 0.25 to 3 hours after dosing at randomization (Day 1) and Week 3 visit and at 0.25 to 3 hours, 4 to 6 hours, and 7 to 12 hours after dosing at Week 6.
|
Before dosing on Day 1, Week 3, Week 6; after dosing at 0.25 to 3 hours on Day 1, Week 3, Week 6; after dosing at 4 to 6 hours and 7 to 12 hours on Week 6
|
合作者和调查者
调查人员
- 研究主任:Johnson & Johnson Pharmaceutical Research & Development L.L.C Clinical Trial、Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
研究记录日期
研究主要日期
学习开始
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (估计)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.
Placebo的临床试验
-
City of Hope Medical CenterNational Cancer Institute (NCI)主动,不招人造血和淋巴细胞肿瘤 | 骨髓纤维化 | 慢性淋巴细胞白血病 | 缓解期成人急性髓性白血病 | 骨髓增生异常综合症 | 缓解期成人急性淋巴细胞白血病 | 骨髓增殖性肿瘤 | 慢性期慢性粒细胞白血病,BCR-ABL1 阳性 | 成人淋巴母细胞淋巴瘤 | 加速期慢性粒细胞白血病,BCR-ABL1 阳性 | HLA-A*0201 阳性细胞存在 | 巨细胞病毒感染 | 成人霍奇金淋巴瘤 | 成人非霍奇金淋巴瘤美国
-
Mila (bMotion Technologies)完全的
-
Universidad Autonoma de MadridCentro Universitario La Salle完全的